Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.84 |
| ▸ | DRD4 | P21917 | 1/20 | 0.84 |
| ▸ | DRD3 | P35462 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377712 | 0.93 | HTR1A (0.86) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL4546512 | 0.92 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL31214695 | 0.92 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL20676053 | 0.92 | HTR1A (0.84) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL678174 | 0.92 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL13804619 | 0.92 | HTR1A (0.84) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL31214696 | 0.92 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL29408712 | 0.92 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL1378993 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL19971703 | 0.89 | HTR1A (0.88) | HTR1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4699027-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2006-05-11 | — | — | US | claimed |
| EP-1539738-A1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2005-06-15 | — | — | EP | claimed |
| WO-2003106449-A1 | NOVEL ARYL-{4-HALO-4-[HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2003-12-24 | — | — | WO | claimed |
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| EP-1539738-B1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL -PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PF MEDICAMENT (FR) | 2009-03-04 | — | — | EP | disclosed |
| EP-1539738-B1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL -PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PF MEDICAMENT (FR) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2006-05-11 | — | — | US | disclosed |
| EP-1539738-A1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2005-06-15 | — | — | EP | disclosed |
| WO-2003106449-A1 | NOVEL ARYL-{4-HALO-4-[HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | CYP4B1, CYP4X1, CYP2E1 | HTR1A 65/4885DRD2 299/4885DRD4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.